Impact of a Digital Solution on Case Preparation and Discussion for Breast Multidisciplinary Tumor Board

November 2019 Vol 10, No 11
Donna Fowler, RN, OCN
University of Missouri,
Columbia, MO
Lincoln Sheets, MD, PhD
University of Missouri,
Columbia, MO
Matthew S. Prime, MD, PhD
Roche Diagnostics,
Basel, Switzerland
Chaohui Guo
Roche Diagnostics,
Basel, Switzerland
Athanasios Siadimas, MSc
Roche Diagnostics,
Basel, Switzerland
Richard D. Hammer, MD
University of Missouri,
Columbia, MO

Background: Multidisciplinary tumor boards (MTBs) provide an interdisciplinary approach for decision-making in cancer care. Efficient preparation and conduction of MTBs are critical for time to treatment and patient outcome. It is largely unknown how digital tumor board solutions impact on case preparation and discussion for MTBs.

Objectives: To evaluate the impact of a digital solution for tumor boards.

Methods: A prospective study was undertaken to evaluate the impact of the NAVIFY Tumor Board (NTB) solution on the accredited breast MTB at the University of Missouri Health Care. NTB is a cloud-based workflow product that integrates with the hospital EMR and displays relevant aggregated data as a holistic patient dashboard. Student’s t test was performed in cases where data met the assumption of normality, and Mann-Whitney test otherwise.

Results: Interim results are presented for 2018 data.

Case Preparation: Time preparation for 20 breast MTBs (120 cases) were evaluated: 10 MTBs (60 cases) in pre-NTB vs 10 MTBs (60 cases) in post-NTB. Total preparation time across cases during pre-NTB was distributed as: 48% contributed by nurse navigator (NN), 42% by pathology resident, 5% by genomics, 6% by radiologist. Because percentage time contribution from geneticists and radiologists was negligible, comparative analysis for these 2 roles was not possible. Impacts on the meeting preparation time vary across roles in pre- vs post-NTB implementation. NN preparation time decreased from 36.0 minutes (SD = 22.6) to 12.8 minutes (SD = 6.5), representing a 64% reduction (t test; P = .008). Pathology resident preparation showed no significant change, 33.1 minutes (SD = 12.1) to 31.1 minutes (SD = 16.5) (t test; P = .3).

Case Discussion: Patient case discussion time was based on data from 24 breast MTBs (144 cases): 14 MTBs (86 cases) in pre-NTB vs 10 MTBs (58 cases) in post-NTB. Case discussion time significantly reduced from 6.6 minutes (SD = 1.5) to 5.3 minutes (SD = 0.9) in pre- vs post-NTB implementation (t test; P = .015).

Conclusion: NNs and pathology residents contributed the most time for case preparation at our institution. The introduction of NTB reduced staff workload and increased the efficiency of case preparation for breast cancer MTBs. The impact was greatest for NNs, possibly because this was a single user compared with pathology residents, who rotated every 8 weeks. In addition, the introduction of NTB standardized and reduced case discussion time at MTBs. Future investigation is needed to examine the impact of NTB based on a larger number of patient cases and from multisites, as well as the impacts on different cancer MTBs.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country